drugset / Trial / NCT04641728
Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer
Phase 2
Unknown
28 enrolled
Saitama Medical University International Medical Center
Aichi Cancer Center · collabCancer Institute Hospital, Japan · collabNational Cancer Center, Japan · collabTokyo University · collab
NaSingle-groupOpen-labelTreatment
Summary
This trial is a multicenter, single-arm, phase 2 study of pembrolizumab in combination with olaparib in recurrent or metastatic cervical cancer patients who had disease progression during or after platinum-based chemotherapy.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2022-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | 300 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |